Open AccessDiagnosis and Treatment of Cutaneous Aspergillosis
Author(s) -
Kyung Duck Park
Publication year - 2021
Publication title -
korean journal of medical mycology/daehan'yi jin'gyun haghoeji
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.101
H-Index - 9
eISSN - 2465-8278
pISSN - 1226-4709
DOI - 10.17966/jmi.2021.26.4.83
Subject(s) - voriconazole , aspergillosis , aspergillus fumigatus , medicine , mycosis , aspergillus flavus , dermatology , amphotericin b , antifungal , aspergillus , surgery , biology , microbiology and biotechnology , immunology
Aspergillosis is an opportunistic mycosis caused by fungi in the genus Aspergillus, mostly A. fumigatus and A. flavus.Typical entry portals in primary cutaneous aspergillosis include burns, trauma sites, surgical wounds, intravenouscatheters, and macerated skin in underlying occlusive dressings. In individuals who are immunocompromised, thedissemination risk is significant. Skin findings range from firm papules and necrotic papulonodules to hemorrhagicbullae and ulcers. The prognosis is poor but improves when the patient is no longer neutropenic or whencorticosteroids are discontinued. Localized primary cutaneous aspergillosis can be excised surgically, followed byoral antifungal administration. For the first-line treatment of pulmonary invasive aspergillosis, isavuconazole andvoriconazole are the preferred agents, whereas liposomal amphotericin B is supported moderately.